Stopping renin-angiotensin-aldosterone system inhibitors in kidney disease - PubMed
5 hours ago
- #chronic kidney disease
- #renin-angiotensin system inhibitors
- #acute kidney injury
- KDIGO guidelines recommend RASi for CKD due to kidney and cardiovascular benefits.
- Real-world data shows low usage and frequent discontinuation of RASi in CKD patients.
- Discontinuing RASi in low eGFR patients shows no benefit on kidney or mortality outcomes.
- Continuation vs. discontinuation of RASi in perioperative periods yields similar outcomes.
- Reinitiating RASi post-AKI and hyperkalemia improves survival and slows kidney disease progression.
- Discontinuation of RASi is generally linked to worse outcomes in CKD, hyperkalemia, and AKI.